Schaeffer's Top Stock Picks for '25

ZYNE Stock Skyrocketing on CBD Gel Update

The drug stock has more than quadrupled this year

Digital Content Manager
May 6, 2019 at 12:11 PM
facebook X logo linkedin


The Food and Drug Administration (FDA) granted Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) "fast track" status for its cannabinoid-based gel, Zygel, used in the treatment of symptoms brought on by the rare genetic disability Fragile X Syndrome (FXS). The stock is up 8% at $12.36 as a result. 

ZYNE has seen some serious growth on the charts in 2019, more than quadrupling this year, and bucking the broad-market trend lower today. The stock just hit a nearly two-year high of $13.06 at the beginning of the month after an impressive seven-day rally. The equity has pulled back some, but managed to ricochet off its 20-day moving average, sending the shares back up the charts. The security is now trading back within striking distance of last week's peak close at $12.52. 

ZYNE Chart May 6

Options bulls are jumping on the stock in response. So far 1,413 Zynerba calls have exchanged hands, almost double the expected amount, compared to just 291 put contracts. The May 12.50 and 15 calls are the most popular so far.

Despite the stock landing on the short-sale restricted list, these bears could be kicking rocks today. Short interest rose 22.3% in the last two reporting periods, now representing a whopping 23.3% of the stock's available float, which could propel the shares higher, should these pessimistic bets begin to unwind. 

On the other hand, analyst sentiment surround the equity has been bullish, with five out of six putting "strong buy" ratings on the table, compared to a lone "hold." Plus, the equity's consensus 12-month target price of $20.08 is at a 62.2% premium to current levels. 

 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?